QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
Free Trial
NYSE:MYOV

Myovant Sciences (MYOV) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)
Free MYOV Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$26.98
▼
$27.00
50-Day Range
$26.88
▼
$26.99
52-Week Range
$7.67
▼
$27.06
Volume
2.26 million shs
Average Volume
1.17 million shs
Market Capitalization
$2.62 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
MYOV stock logo

About Myovant Sciences Stock (NYSE:MYOV)

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

MYOV Stock News Headlines

April 18, 2024 | uk.finance.yahoo.com
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
January 15, 2024 | forbes.com
2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Year
April 19, 2024 | DTI (Ad)
With the “Bitcoin Loophole” you can supercharge the gains by 10x or more
Thanks to this newly discovered Bitcoin Loophole, you can now trade Bitcoin in any regular brokerage account… And not only that… you can use it to supercharge the gains of Bitcoin by 10x or more! You see, thanks to one unique investor's brand new discovery - anyone with a regular brokerage account can now tap into the most explosive asset in history. That means you can skip the hassle of opening a Coinbase account… Bypass the fees and hard-to-remember passwords…
January 11, 2024 | finance.yahoo.com
Global $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Region
January 3, 2024 | finance.yahoo.com
ReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
December 28, 2023 | dailymail.co.uk
Vivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...
December 8, 2023 | finance.yahoo.com
Metastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsight
November 21, 2023 | markets.businessinsider.com
NCCN Announces Funding for Advanced Prostate Cancer Research Projects
April 19, 2024 | Darwin (Ad)
Your Next Portfolio Star: Revealing 2024's Top Stock Pick
We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
October 22, 2023 | barrons.com
Myovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
September 26, 2023 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV
September 12, 2023 | marketwatch.com
4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chief
August 29, 2023 | msn.com
Vivek Ramaswamy claims he is too busy campaigning to give evidence
August 29, 2023 | msn.com
2024 Presidential candidate Vivek Ramaswamy trying to duck legal battle over his biotech empire
August 28, 2023 | msn.com
EXCLUSIVE: Vivek Ramaswamy claims he is too busy campaigning for President to give evidence in multi-million dollar court case
August 28, 2023 | msn.com
Vivek Ramaswamy cites campaign to duck deposition in buyout suit
August 24, 2023 | msn.com
Bill Ackman Tells Vivek Ramaswamy How To Run For President
August 24, 2023 | finance.yahoo.com
Uterine Fibroids Treatment Global Market Report 2023
August 21, 2023 | benzinga.com
Presidential Hopeful Ramaswamy Predicts US Recession In 2024
July 4, 2023 | uk.finance.yahoo.com
Hormone Therapy Global Market Report 2023
June 26, 2023 | finance.yahoo.com
Health in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness Month
June 22, 2023 | benzinga.com
Antibacterial Drugs Market to Reach US$ 62 Billion by 2031 | Fact.MR Report
May 18, 2023 | finance.yahoo.com
Women's Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.
May 17, 2023 | finance.yahoo.com
Myovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine Fibroids
May 16, 2023 | marketwatch.com
Endometriosis Treatment Drugs Market Top Competitors and Prediction Till 2030
May 10, 2023 | marketwatch.com
Metastatic Prostate Cancer Treatment Market Size: Growth Dynamics from 2023 to 2031
May 8, 2023 | marketwatch.com
Menstrual Cramps Treatment Market worth growing 4.0% at a CAGR by 2027
See More Headlines
Receive MYOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2021
Today
4/19/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:MYOV
Previous Symbol
NASDAQ:MYOV
CUSIP
N/A
CIK
1679082
Web
www.myovant.com
Phone
442074003351
Fax
N/A
Employees
407
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-205,980,000.00
Net Margins
-48.47%
Pretax Margin
-42.81%
Return on Equity
N/A
Return on Assets
-39.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.57
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$230.97 million
Price / Sales
11.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($5.04) per share
Price / Book
-5.35

Miscellaneous

Outstanding Shares
97,240,000
Free Float
95,388,000
Market Cap
$2.62 billion
Optionable
Not Optionable
Beta
2.17
10 Best Cheap Stocks to Buy Now Cover
10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

MYOV Stock Analysis - Frequently Asked Questions

How were Myovant Sciences' earnings last quarter?

Myovant Sciences Ltd. (NYSE:MYOV) issued its quarterly earnings data on Tuesday, October, 26th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.11. The firm earned $77.90 million during the quarter, compared to analysts' expectations of $72.67 million. During the same quarter in the prior year, the firm posted ($0.75) EPS.

What other stocks do shareholders of Myovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

When did Myovant Sciences IPO?

Myovant Sciences (MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

This page (NYSE:MYOV) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith